EdwinDeJesusMDFACP, FIDSA
Infectious Disease • Orlando, FLHIV/AIDS Medicine, STD Medicine
Medical Director - Orlando Immunology Center and Assistant Professor - UCF College of Medicine
Dr. DeJesus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1707 N Mills Ave
Orlando, FL 32803Phone+1 407-647-3960Fax+1 407-413-5775
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalFellowship, Infectious Disease, 1991 - 1993- Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1988 - 1991
University of Puerto Rico School of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 1993 - 2026
PA State Medical License 1990 - 1994
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Centricity Practice Solution EMR, GE Healthcare, 2014
Clinical Trials
- Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
- Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA) Start of enrollment: 2006 Apr 01
- Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A Start of enrollment: 2006 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 211 citationsEmtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomis...Kenneth H. Mayer, Jean-Michel Molina, Melanie A. Thompson, Peter L. Anderson, Karam Mounzer
Lancet. 2020-07-25 - 5 citationsSafety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.Joseph J Eron, Susan J Little, Gordon Crofoot, Paul Cook, Peter J Ruane
The Lancet. HIV. 2024-03-01 - 583 citationsMaraviroc for Previously Treated Patients with R5 HIV-1 InfectionRoy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus
The New England Journal of Medicine. 2008-10-02
Journal Articles
- Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Edwin Dejesus, Cyril Llamoso, The New England Journal of Medicine
Press Mentions
Treatment-Related Early Discontinuations and Adverse Events Among Newly Diagnosed People Living with HIV Initiating Integrase Inhibitors in a Real-World SettingFebruary 1st, 2023- Orlando Trial for New Types of COVID-19 Monoclonal Antibody Treatment Seeks ParticipantsDecember 15th, 2021
- 'Elite Neutralizing' Antibody Demonstrates Long-Term Viral Suppression in Persons Living with HIV in Phase 1 TrialOctober 14th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
